These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

409 related articles for article (PubMed ID: 28247712)

  • 21. TP53 alterations as a potential diagnostic marker in superficial bladder carcinoma and in patients serum, plasma and urine samples.
    Dahse R; Utting M; Werner W; Schimmel B; Claussen U; Junker K
    Int J Oncol; 2002 Jan; 20(1):107-15. PubMed ID: 11743649
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Molecular changes during progression from nonmuscle invasive to advanced urothelial carcinoma.
    Sjödahl G; Eriksson P; Patschan O; Marzouka NA; Jakobsson L; Bernardo C; Lövgren K; Chebil G; Zwarthoff E; Liedberg F; Höglund M
    Int J Cancer; 2020 May; 146(9):2636-2647. PubMed ID: 31609466
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Meta-Analysis of the Luminal and Basal Subtypes of Bladder Cancer and the Identification of Signature Immunohistochemical Markers for Clinical Use.
    Dadhania V; Zhang M; Zhang L; Bondaruk J; Majewski T; Siefker-Radtke A; Guo CC; Dinney C; Cogdell DE; Zhang S; Lee S; Lee JG; Weinstein JN; Baggerly K; McConkey D; Czerniak B
    EBioMedicine; 2016 Oct; 12():105-117. PubMed ID: 27612592
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Molecular changes in development and progression of urothelial carcinoma].
    Hartmann A
    Verh Dtsch Ges Pathol; 2003; 87():172-84. PubMed ID: 16888910
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Spectrum of genetic mutations in de novo PUNLMP of the urinary bladder.
    Rodriguez Pena MDC; Tregnago AC; Eich ML; Springer S; Wang Y; Taheri D; Ertoy D; Fujita K; Bezerra SM; Cunha IW; Raspollini MR; Yu L; Bivalacqua TJ; Papadopoulos N; Kinzler KW; Vogelstein B; Netto GJ
    Virchows Arch; 2017 Dec; 471(6):761-767. PubMed ID: 28597078
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Recent Advances in the Diagnosis and Management of Bladder Cancer.
    Zhang X; Han C; He J
    Cell Biochem Biophys; 2015 Sep; 73(1):11-5. PubMed ID: 25716337
    [TBL] [Abstract][Full Text] [Related]  

  • 27.
    Weyerer V; Eckstein M; Strissel PL; Wullweber A; Lange F; Tögel L; Geppert CI; Sikic D; Taubert H; Wach S; Wullich B; Hartmann A; Stoehr R; Giedl J
    Genes (Basel); 2021 Feb; 12(2):. PubMed ID: 33562516
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mutations in FGFR3 and PIK3CA, singly or combined with RAS and AKT1, are associated with AKT but not with MAPK pathway activation in urothelial bladder cancer.
    Juanpere N; Agell L; Lorenzo M; de Muga S; López-Vilaró L; Murillo R; Mojal S; Serrano S; Lorente JA; Lloreta J; Hernández S
    Hum Pathol; 2012 Oct; 43(10):1573-82. PubMed ID: 22417847
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Consistent genomic alterations in carcinoma in situ of the urinary bladder confirm the presence of two major pathways in bladder cancer development.
    Zieger K; Marcussen N; Borre M; Ørntoft TF; Dyrskjøt L
    Int J Cancer; 2009 Nov; 125(9):2095-103. PubMed ID: 19637316
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Role of activating fibroblast growth factor receptor 3 mutations in the development of bladder tumors.
    Zieger K; Dyrskjøt L; Wiuf C; Jensen JL; Andersen CL; Jensen KM; Ørntoft TF
    Clin Cancer Res; 2005 Nov; 11(21):7709-19. PubMed ID: 16278391
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Molecular Biomarkers in Bladder Cancer: Novel Potential Indicators of Prognosis and Treatment Outcomes.
    Nagata M; Muto S; Horie S
    Dis Markers; 2016; 2016():8205836. PubMed ID: 26924873
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Multiplex PCR and Next Generation Sequencing for the Non-Invasive Detection of Bladder Cancer.
    Ward DG; Baxter L; Gordon NS; Ott S; Savage RS; Beggs AD; James JD; Lickiss J; Green S; Wallis Y; Wei W; James ND; Zeegers MP; Cheng KK; Mathews GM; Patel P; Griffiths M; Bryan RT
    PLoS One; 2016; 11(2):e0149756. PubMed ID: 26901314
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Promoter hypermethylation of the 14-3-3 sigma, SYK and CAGE-1 genes is related to the various phenotypes of urinary bladder carcinomas and associated with progression of transitional cell carcinomas.
    Kunze E; Wendt M; Schlott T
    Int J Mol Med; 2006 Oct; 18(4):547-57. PubMed ID: 16964403
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Analysis of Point Mutations in Clinical Samples of Urothelial Carcinoma.
    Alamyar M; Zwarthoff EC
    Methods Mol Biol; 2018; 1655():19-28. PubMed ID: 28889374
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CDKN2A homozygous deletion is associated with muscle invasion in FGFR3-mutated urothelial bladder carcinoma.
    Rebouissou S; Hérault A; Letouzé E; Neuzillet Y; Laplanche A; Ofualuka K; Maillé P; Leroy K; Riou A; Lepage ML; Vordos D; de la Taille A; Denoux Y; Sibony M; Guyon F; Lebret T; Benhamou S; Allory Y; Radvanyi F
    J Pathol; 2012 Jul; 227(3):315-24. PubMed ID: 22422578
    [TBL] [Abstract][Full Text] [Related]  

  • 36. MicroRNAs: Key Players in Bladder Cancer.
    Li Q; Wang H; Peng H; Huang Q; Huyan T; Huang Q; Yang H; Shi J
    Mol Diagn Ther; 2019 Oct; 23(5):579-601. PubMed ID: 31325035
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Genetic diversity of urinary bladder cancer and the risk of recurrence based on mutation analysis.
    Traczyk-Borszynska M; Borkowska E; Jablonowski Z; Jedrzejczyk A; Pietrusinski M; Kaluzewski B; Sosnowski M; Borowiec M
    Neoplasma; 2016; 63(6):952-960. PubMed ID: 27596295
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Molecular Subtype Profiling of Urothelial Carcinoma Using a Subtype-Specific Immunohistochemistry Panel.
    Sjödahl G
    Methods Mol Biol; 2018; 1655():53-64. PubMed ID: 28889377
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Genetic studies and molecular markers of bladder cancer.
    Cordon-Cardo C; Sheinfeld J; Dalbagni G
    Semin Surg Oncol; 1997; 13(5):319-27. PubMed ID: 9259087
    [TBL] [Abstract][Full Text] [Related]  

  • 40. No mutations of FGFR3 in normal urothelium in the vicinity of urothelial carcinoma of the bladder harbouring activating FGFR3 mutations in patients with bladder cancer.
    Otto W; Denzinger S; Bertz S; Gaumann A; Wild PJ; Hartmann A; Stoehr R
    Int J Cancer; 2009 Nov; 125(9):2205-8. PubMed ID: 19621447
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.